Pulmonx (LUNG) Stock Price, News & Analysis

Company Overview

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe. Pulmonx supports its commercial portfolio with comprehensive physician training programs, ongoing clinical research collaborations, and robust post-market surveillance initiatives. These efforts help validate long-term safety and efficacy, while also guiding future enhancements and potential label expansions for its technologies.

Headquartered in Redwood City, California, Pulmonx maintains an international presence through offices and distribution partners in Europe. Under the leadership of President and Chief Executive Officer Antonio Pizarro, the company continues to advance its mission of improving the quality of life for patients with obstructive lung diseases. Pulmonx remains committed to innovation in minimally invasive therapies and to building strategic relationships with physicians and healthcare institutions worldwide.

Key Stats

• Today's Range: $1.22 to $1.30
• 50-Day Range: $1.17 to $2.02
• 52-Week Range: $1.13 to $3.88
• Volume: 195,866 shs
• Average Volume: 481,725 shs
• Market Capitalization: $52.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.38
• Consensus Rating: Hold

Pulmonx Stock Analysis - MarketRank™

Pulmonx scored higher than 45% of companies evaluated by MarketBeat, and ranked 540th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Pulmonx has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Pulmonx has a consensus price target of $5.38, representing about 335.5% upside from its current price of $1.24.

Amount of Analyst Coverage

Pulmonx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pulmonx are expected to grow in the coming year, from ($1.13) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmonx is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmonx is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmonx has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.15% of the float of Pulmonx has been sold short.

Short Interest Ratio / Days to Cover

Pulmonx has a short interest ratio ("days to cover") of 13.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulmonx has recently decreased by 1.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmonx does not currently pay a dividend.

Dividend Growth

Pulmonx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.03

News Sentiment

Pulmonx has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Pulmonx this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for LUNG on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $140,519.00 in company stock.

Percentage Held by Insiders

6.80% of the stock of Pulmonx is held by insiders.

Percentage Held by Institutions

91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LUNG Stock Analysis - Frequently Asked Questions

How have LUNG shares performed this year?

Pulmonx's stock was trading at $2.21 at the beginning of the year. Since then, LUNG shares have decreased by 44.1% and is now trading at $1.2350.

How were Pulmonx's earnings last quarter?

Pulmonx Corporation (NASDAQ:LUNG) released its earnings results on Wednesday, April, 29th. The company reported ($0.33) EPS for the quarter, meeting analysts' consensus estimates of ($0.33). The company had revenue of $20.59 million for the quarter, compared to the consensus estimate of $20.43 million. Pulmonx had a negative net margin of 60.09% and a negative trailing twelve-month return on equity of 92.94%.
Read the conference call transcript.

When did Pulmonx IPO?

Pulmonx (LUNG) raised $175 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 10,000,000 shares at a price of $17.00-$18.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Pulmonx's major shareholders?

Pulmonx's top institutional shareholders include Dimensional Fund Advisors LP (0.34%), Berger Financial Group Inc (0.13%), Perkins Capital Management Inc. (0.10%) and R Squared Ltd (0.05%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Srikanth Radhakrishnan, Daniel P Florin, Richard Ferrari and John Mckune.
View institutional ownership trends.

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulmonx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 4/29/2026
• Today: 5/08/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LUNG
• CIK: 1127537
• Web: pulmonx.com
• Phone: 1-650-364-0400
• Fax: N/A
• Employees: 250
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Pulmonx: $5.38
• High Price Target: $14.00
• Low Price Target: $2.50
• Potential Upside/Downside: +335.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54 million
• Net Margins: -60.09%
• Pretax Margin: -59.37%
• Return on Equity: -92.94%
• Return on Assets: -39.80%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 4.91
• Quick Ratio: 4.28

Sales & Book Value

• Annual Sales: $90.50 million
• Price / Sales: 0.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 42,240,000
• Free Float: 39,365,000
• Market Cap: $52.17 million
• Optionable: Optionable
• Beta: 0.18